Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA — Michael S. Hofman (2017) | RDL Network
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
Shahneen Sandhu, John Violet, Justin Ferdinandus, Sue-Ping Thang, Amir Iravani, Christina Guo, Grace Kong, Aravind Ravi Kumar, Timothy Akhurst, Alexis Beaulieu, Declan G. Murphy, Jennifer Mooi, Ben Tran, Guy C. Toner, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Timothy Akhurst, Jennifer Mooi, Christina Guo, Ben Tran, Price Jackson, Mark Scalzo, Peter Eu, Scott Williams, Shahneen Sandhu
Michael S. Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney J. Hicks
Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G. Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott Williams, Shahneen Sandhu
Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun Azad, Alexander W. Wyatt
Discussion(0)
No comments yet. Be the first to comment.